Diabetes mellitus and drug-induced parkinsonism: A case-control study

Journal of the Neurological Sciences

Volumn 284, Issue 1-2, 2009, Pages 140-143

  Ma, Hyeo Il ^a   Kim, Jin Hyuck ^b   Chu, Min Kyung ^a   Oh, Mi Sun ^a   Yu, Kyung Ho ^a   Kim, Jooyong ^a   Hahm, Woong ^b   Kim, Yun Joong ^a,c   Lee, Byung Chul ^a  

^a Hallym University College of Medicine   (South Korea)

^b Keyo Medical Foundation   (South Korea)

^c Hallym University   (South Korea)

Author keywords

Case control study; Diabetes mellitus; Drug induced parkinsonism; Risk factor

Indexed keywords

CHLORPROMAZINE; CLEBOPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUNARIZINE; METOCLOPRAMIDE; PERPHENAZINE; RISPERIDONE; SULPIRIDE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; DIABETES MELLITUS; DRUG CONTRAINDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STROKE;

AGE OF ONSET; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE SUSCEPTIBILITY; DOPAMINE ANTAGONISTS; FEMALE; GASTROPARESIS; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SINGLE-BLIND METHOD; STROKE; SULPIRIDE;

EID: 67849109838     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.05.006     Document Type: Article

References (42)

1. Bower J.H., Maraganore D.M., McDonnell S.K., and Rocca W.A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52 (1999) 1214-1220
2. Benito-Leon J., Bermejo-Pareja F., Morales-Gonzalez J.M., Porta-Etessam J., Trincado R., Vega S., et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 62 (2004) 734-741
3. de Lau L.M., Giesbergen P.C., de Rijk M.C., Hofman A., Koudstaal P.J., and Breteler M.M. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63 (2004) 1240-1244
4. Barbosa M.T., Caramelli P., Maia D.P., Cunningham M.C., Guerra H.L., Lima-Costa M.F., et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 21 (2006) 800-808
5. Kuzuhara S. Drug-induced parkinsonism. Nippon Rinsho 55 (1997) 112-117
6. Negrotti A., and Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 12 (1997) 107-110
7. Lee P.H., Kim J.S., Shin D.H., Yoon S.N., and Huh K. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 77 (2006) 372-374
8. Rochon P.A., Stukel T.A., Sykora K., Gill S., Garfinkel S., Anderson G.M., et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 165 (2005) 1882-1888
9. Tolosa E., Coelho M., and Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18 Suppl 7 (2003) S28-33
10. Van Gerpen J.A. Drug-induced parkinsonism. Neurologist 8 (2002) 363-370
11. Sethi K.D., Patel B., and Meador K.J. Metoclopramide-induced parkinsonism. South Med J 82 (1989) 1581-1582
12. Pasricha P.J., Pehlivanov N., Sugumar A., and Jankovic J. Drug insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 138-148
13. Chabolla D.R., Maraganore D.M., Ahlskog J.E., O Brien P.C., and Rocca W.A. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 73 (1998) 724-727
14. Negrotti A., Calzetti S., and Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 13 (1992) 261-264
15. Fahn S., and Przedborski S. Parkinsonism. In: Rowland L.P. (Ed). Merrits Neurology (2000), Lippincott Williams and Wilkins, Philadelphia 679-693
16. Molho E.S., and Factor S.A. Secondary causes of parkinsonism. In: Adler C.H., and Ahlskog J.E. (Eds). Parkinsons Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician (2000), Humana Press, Totowa, NJ 211-214
17. Dean C.E., Kuskowski M.A., and Caligiuri M.P. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J Clin Psychopharmacol 26 (2006) 560-565
18. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
19. Lee B.C., Hwang S.H., Jung S., Yu K.H., Lee J.H., Cho S.J., et al. The Hallym Stroke Registry: a web-based stroke data bank with an analysis of 1654 consecutive patients with acute stroke. Eur Neurol 54 (2005) 81-87
20. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
21. Hu G., Jousilahti P., Bidel S., Antikainen R., and Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007) 842-847
22. Lee P.H., Yeo S.H., Yong S.W., and Kim Y.J. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 78 (2007) 1250-1252
23. Zhang Z.X., Roman G.C., Hong Z., Wu C.B., Qu Q.M., Huang J.B., et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365 (2005) 595-597
24. Marras C., and Tanner C.M. Epidemiology of Parkinson's disease. In: Watts R.L., and Koller W.C. (Eds). Movement disorders: neurologic principles and practice. 2nd edn. (2004), McGraw-Hill medical publishing, New York 177-196
25. Kimura H., Kurimura M., Wada M., Kawanami T., Kurita K., Suzuki Y., et al. Female preponderance of Parkinson's disease in Japan. Neuroepidemiology 21 (2002) 292-296
26. Kim J.S., and Sohn Y.H. Current status of Parkinson's disease treatment in Korea. Parkinsonism Relat Disord 9 Suppl 2 (2003) S99-104
27. Kim S.M., Lee J.S., Lee J., Na J.K., Han J.H., Yoon D.K., et al. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care 29 (2006) 226-231
28. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., Swanson P.D., and Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 12 (2006) 185-189
29. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G., and Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37 (2006) 1184-1188
30. Simon K.C., Chen H., Schwarzschild M., and Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69 (2007) 1688-1695
31. Becker C., Brobert G.P., Johansson S., Jick S.S., and Meier C.R. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 31 (2008) 1808-1812
32. Driver J.A., Smith A., Buring J.E., Gaziano J.M., Kurth T., and Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31 (2008) 2003-2005
33. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69 (1993) 125-130
34. Pressley J.C., Louis E.D., Tang M.X., Cote L., Cohen P.D., Glied S., et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60 (2003) 87-93
35. Lee B.C., and Roh J.K. International experience in stroke registries: Korean Stroke Registry. Am J Prev Med 31 (2006) S243-245
36. Woerner M.G., Saltz B.L., Kane J.M., Lieberman J.A., and Alvir J.M. Diabetes and development of tardive dyskinesia. Am J Psychiatry 150 (1993) 966-968
37. Postuma R.B., and Lang A.E. Hemiballism: revisiting a classic disorder. Lancet Neurol 2 (2003) 661-668
38. Shimizu H., Shimomura Y., Takahashi M., Kobayashi I., and Kobayashi S. Dopamine receptor in the streptozotocin-induced diabetic rats. Exp Clin Endocrinol 95 (1990) 263-266
39. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.R., and Rosenkeck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159 (2002) 561-566
40. Toprak O., Cirit M., Ersoy R., Uzüm A., Ozümer O., Cobanoǧlu A., Tanrisev M., Güleç D., and Cetinkalp S. New-onset type II diabetes mellitus, hyperosmolar non-ketotic coma, rhabodomyolysis and acute renal failure in a patient treated with sulpiride. Nephrol Dial Transplant 20 (2005) 662-663
41. Tonini M., Cipollina L., Poluzzi E., Crema F., Corazza G.R., and De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19 (2004) 379-380
42. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 356 (2007) 820-829